Compare SWX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SWX | ERAS |
|---|---|---|
| Founded | 1931 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.3B | 5.5B |
| IPO Year | 2017 | 2021 |
| Metric | SWX | ERAS |
|---|---|---|
| Price | $90.27 | $19.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $87.40 | $14.25 |
| AVG Volume (30 Days) | 379.9K | ★ 6.0M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | ★ 120.29 | 36.23 |
| EPS | ★ 6.08 | N/A |
| Revenue | ★ $5,433,972,000.00 | N/A |
| Revenue This Year | $18.48 | N/A |
| Revenue Next Year | $2.61 | N/A |
| P/E Ratio | $14.80 | ★ N/A |
| Revenue Growth | ★ 9.56 | N/A |
| 52 Week Low | $66.93 | $1.06 |
| 52 Week High | $93.44 | $24.28 |
| Indicator | SWX | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 55.28 | 54.91 |
| Support Level | $76.66 | $1.98 |
| Resistance Level | $93.44 | N/A |
| Average True Range (ATR) | 1.63 | 1.98 |
| MACD | -0.19 | 0.13 |
| Stochastic Oscillator | 45.80 | 49.95 |
Southwest Gas Holdings Inc is a utility company engaged in the purchasing, distributing, and transporting of natural gas in the American Southwest. The company segments its activities into natural gas distribution segment. The Natural gas distribution segment encompasses the company's core natural gas business as distributors in the states of Arizona and Nevada. Its division is responsible for roughly half of Southwest Gas' total revenue through the sale of natural gas to mainly residential and small commercial customers.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.